World Journal of Urology

, Volume 26, Issue 1, pp 59–65

Survivin: a promising biomarker for detection and prognosis of bladder cancer

  • Vitaly Margulis
  • Yair Lotan
  • Shahrokh F. Shariat
Topic Paper

Abstract

Survivin is a 16.5 kDa member of the inhibitor of apoptosis protein family that is overexpressed in many malignancies but rarely detected in normal differentiated adult tissues. Functionally, Survivin inhibits apoptosis, promotes cell proliferation, and induces/enhances angiogenesis. In transitional cell carcinoma of the urinary bladder, Survivin has been shown to be a promising biomarker for cancer diagnosis, prognosis and prediction of response to intravesical or systemic therapies. Moreover, in pre-clinical bladder tumor models, inhibition of Survivin expression and/or function has been shown to impede tumor cell proliferation, and markedly induce spontaneous or chemotherapy induced apoptosis. These preliminary findings should now be confirmed in large prospective trials. Furthermore, simplified, quantitative and reproducible assays need to be developed and validated for the detection of Survivin and its different isoforms.

Keywords

Survivin Urine Detection Target Prognosis Bladder cancer 

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRefGoogle Scholar
  2. 2.
    Landman J, Chang Y, Kavaler E et al (1998) Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 52:398–402PubMedCrossRefGoogle Scholar
  3. 3.
    Lahme S, Bichler KH, Feil G et al (2003) Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer. Adv Exp Med Biol 539:111–119PubMedGoogle Scholar
  4. 4.
    Shariat SF, Casella R, Khoddami SM et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626–630PubMedCrossRefGoogle Scholar
  5. 5.
    Botteman MF, Pashos CL, Redaelli A et al (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330PubMedCrossRefGoogle Scholar
  6. 6.
    Gerl R, Vaux DL (2005) Apoptosis in the development and treatment of cancer. Carcinogenesis 26:263–270PubMedCrossRefGoogle Scholar
  7. 7.
    Li F, Ling X (2006) Survivin study: an update of “what is the next wave”? J Cell Physiol 208:476–486PubMedCrossRefGoogle Scholar
  8. 8.
    Altieri DC (2004) Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 92:656–663PubMedCrossRefGoogle Scholar
  9. 9.
    Deveraux QL, Reed JC (1999) IAP family proteins–suppressors of apoptosis. Genes Dev 13:239–252PubMedGoogle Scholar
  10. 10.
    Caldas H, Jiang Y, Holloway MP et al (2005) Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24:1994–2007PubMedCrossRefGoogle Scholar
  11. 11.
    Ceballos-Cancino G, Espinosa M, Maldonado V et al (2007) Regulation of mitochondrial Smac/DIABLO-selective release by survivin. OncogeneGoogle Scholar
  12. 12.
    Speliotes EK, Uren A, Vaux D et al (2000) The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 6:211–223PubMedCrossRefGoogle Scholar
  13. 13.
    Giodini A, Kallio MJ, Wall NR et al (2002) Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62:2462–2467PubMedGoogle Scholar
  14. 14.
    Blanc-Brude OP, Mesri M, Wall NR et al (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683–2692PubMedGoogle Scholar
  15. 15.
    Kawasaki H, Toyoda M, Shinohara H et al (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026–2032PubMedCrossRefGoogle Scholar
  16. 16.
    Tu SP, Jiang XH, Lin MC et al (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724–7732PubMedGoogle Scholar
  17. 17.
    Smith SD, Wheeler MA, Plescia J et al (2001) Urine detection of survivin and diagnosis of bladder cancer. Jama 285:324–328PubMedCrossRefGoogle Scholar
  18. 18.
    Weikert S, Christoph F, Schrader M et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116:100–104PubMedCrossRefGoogle Scholar
  19. 19.
    Shariat SF, Ashfaq R, Roehrborn CG et al (2005) Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 174:2046–2050PubMedCrossRefGoogle Scholar
  20. 20.
    Herr HW (1997) Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 15:84–88PubMedCrossRefGoogle Scholar
  21. 21.
    Schultz IJ, Kiemeney LA, Karthaus HF et al (2004) Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 50:1425–1428PubMedCrossRefGoogle Scholar
  22. 22.
    Gazzaniga P, Gradilone A, Giuliani L et al (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14:85–90PubMedCrossRefGoogle Scholar
  23. 23.
    Swana HS, Grossman D, Anthony JN et al (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341:452–453PubMedCrossRefGoogle Scholar
  24. 24.
    Ku JH, Kwak C, Lee HS et al (2004) Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 171:631–635PubMedCrossRefGoogle Scholar
  25. 25.
    Lehner R, Lucia MS, Jarboe EA et al (2002) Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 10:134–138PubMedCrossRefGoogle Scholar
  26. 26.
    Karam JA, Lotan Y, Ashfaq R et al (2007) Survivin expression in patients with non-muscle invasive urothelial cell carcinoma of the bladder. Urology (in press)Google Scholar
  27. 27.
    Hausladen DA, Wheeler MA, Altieri DC et al (2003) Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 170:230–234PubMedCrossRefGoogle Scholar
  28. 28.
    Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422, discussion 2422PubMedCrossRefGoogle Scholar
  29. 29.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMedGoogle Scholar
  30. 30.
    Shariat SF, Ashfaq R, Karakiewicz PI et al (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109:1106–1113PubMedCrossRefGoogle Scholar
  31. 31.
    Karam JA, Lotan Y, Karakiewicz PI et al (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8:128–136PubMedCrossRefGoogle Scholar
  32. 32.
    Duffy MJ, O’Donovan N, Brennan DJ et al (2007) Survivin: a promising tumor biomarker. Cancer Lett 249:49–60PubMedCrossRefGoogle Scholar
  33. 33.
    Als AB, Dyrskjot L, von der Maase H et al (2007) Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer. Clin Cancer Res 13:4407–4414PubMedCrossRefGoogle Scholar
  34. 34.
    Fuessel S, Herrmann J, Ning S et al (2006) Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 232:243–254PubMedCrossRefGoogle Scholar
  35. 35.
    Hou JQ, He J, Wang XL et al (2006) Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin Med J (Engl) 119:1734–1739Google Scholar
  36. 36.
    Ning S, Fuessel S, Kotzsch M et al (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065–1071PubMedGoogle Scholar
  37. 37.
    Wang ZH, Ye Q, Huang DY et al (2007) Antisense RNA of survivin gene enhances the taxol-induced apoptosis and sensitivity to chemotherapy drugs in bladder cancer cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi 87:419–422PubMedGoogle Scholar
  38. 38.
    Wuttig D, Kunze D, Fuessel S et al (2007) Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? Int J Oncol 30:1317–1324PubMedGoogle Scholar
  39. 39.
    Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54PubMedCrossRefGoogle Scholar
  40. 40.
    Wang H, Xi X, Kong X et al (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 130:487–490PubMedCrossRefGoogle Scholar
  41. 41.
    Moussa O, Abol-Enein H, Bissada NK et al (2006) Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 175:2312–2316PubMedCrossRefGoogle Scholar
  42. 42.
    Kenney DM, Geschwindt RD, Kary MR et al (2007) Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 28:57–62PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Vitaly Margulis
    • 1
  • Yair Lotan
    • 2
  • Shahrokh F. Shariat
    • 2
  1. 1.Department of UrologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of UrologyThe University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations